B

Belluscura PLC
LSE:BELL

Watchlist Manager
Belluscura PLC
LSE:BELL
Watchlist
Price: 10.25 GBX 7.89% Market Closed
Market Cap: 17.3m GBX
Have any thoughts about
Belluscura PLC?
Write Note

Belluscura PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Belluscura PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
Belluscura PLC
LSE:BELL
Cash & Cash Equivalents
$2m
CAGR 3-Years
58%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Cash & Cash Equivalents
$568m
CAGR 3-Years
-26%
CAGR 5-Years
33%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash & Cash Equivalents
$346.4m
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
11%
EKF Diagnostics Holdings PLC
LSE:EKF
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-22%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
Angle PLC
LSE:AGL
Cash & Cash Equivalents
ÂŁ17.9m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-32%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
No Stocks Found

Belluscura PLC
Glance View

Market Cap
16.3m GBX
Industry
Health Care

Belluscura Plc engages in the provision of medical devices. The Company’s product, the X-PLO2R, is a lightweight portable oxygen concentrator (POC), which is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company focuses on devices and treatments involving oxygen. The X-PLO2R DX is designed to produce approximately six-liters pulse dose oxygen and approximately two-liters of flow oxygen. The firm is focused on developing the medical devices for treating people who are suffering from chronic lung diseases, such as the chronic obstructive pulmonary disease (COPD), respiratory distress caused by coronavirus disease (COVID-19), and other respiratory disorders.

BELL Intrinsic Value
11.52 GBX
Undervaluation 11%
Intrinsic Value
Price
B

See Also

What is Belluscura PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
2m USD

Based on the financial report for Dec 31, 2023, Belluscura PLC's Cash & Cash Equivalents amounts to 2m USD.

What is Belluscura PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
31%

Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for Belluscura PLC have been 58% over the past three years , 31% over the past five years .

Back to Top